Tumour-specific uptake of anti-cancer drugs: The future is here

Current Drug Metabolism

Volumn 13, Issue 1, 2012, Pages 4-21

  Caraglia, Michele ^a   Marra, Monica ^a   Misso, Gabriella ^a   Lamberti, Monica ^a   Salzano, Giuseppina ^b   De Rosa, Giuseppe ^b   Abbruzzese, Alberto ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Biodistribution; Chemotherapy; Drug delivery systems; Liposome; Micelle; Nanoparticle; Pharmacokinetics; Polyetilenglicole

Indexed keywords

ANESTHETIC AGENT; ANTHRACYCLINE; ANTIBODY; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; APTAMER; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CREMOPHOR; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETHYLENE OXIDE; EXCIPIENT; FOTEMUSTINE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; METHOTREXATE; NANOPARTICLE; PACLITAXEL; PEPTIDE; PHOTOSENSITIZING AGENT; SEDATIVE AGENT; TAXANE DERIVATIVE; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER TISSUE; CORTICOSTEROID THERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG EXTRAVASATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG UPTAKE; ENHANCED PERMEABILITY AND RETENTION; ERYTHEMA MULTIFORME; EXTRAVASATION; HAND FOOT SYNDROME; HOT FLUSH; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOLECULE; MUCOSA INFLAMMATION; NAIL COLOR DEFECT; NEOPLASM; NEUROPATHY; NONHUMAN; OPSONIZATION; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; RETICULOENDOTHELIAL SYSTEM; REVIEW; SKIN TOXICITY; SUSTAINED DRUG RELEASE; TOXIC EPIDERMAL NECROLYSIS; TUMOR; TUMOR CELL; VISCOSITY;

EID: 84857577657     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012798356871     Document Type: Review

References (197)

1. Cheong, I.; Huang, X.; Thornton, K.; Diaz, L.A.Jr.; Zhou, S. Targeting Cancer with Bugs and Liposomes: Ready, Aim, Fire. Cancer Res., 2007, 67(20), 9605-9608. (Pubitemid 47621203)
2. Wyatt, A.J.; Leonard, G.D.; Sachs, D.L. Cutaneous reactions to chemotherapy and their management. Am. J. Clin. Dermatol., 2006, 7(1), 45-63.
3. Oncology Nursing Society. Cancer chemotherapy and biotherapy guidelines and recommendations for practice: Module XXII. Oncology Nursing Press: Pittsburgh, PA, 2002.
4. Susser, W.S.; Whitaker-Worth, D.L.; Grant-Kels, J.M. Mucocutaneous reactions to chemotherapy. J. Am. Acad. Dermatol., 1999, 40, 367-398. (Pubitemid 29115299)
5. Yosowitz, P.; Ekland, D.A.; Shaw, R.C.; Parsons, R.W. Peripheral intravenous infiltration necrosis. Ann. Surg., 1975, 182, 553-556.
6. Kraft, A.; Weinig, A.; Berger, D.P.; Winterhalter, B.R. Anthrazyklin-Extravasate. Onkologie, 2000, 6, 674-686.
7. Ignoffo, R.J.; Friedman, M.A. Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat. Rev., 1980, 7, 17-27. (Pubitemid 11236806)
8. Larson, D.L. Treatment of tissue extravasation by antitumor agents. Cancer, 1982, 49,1796-1799. (Pubitemid 12153449)
9. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer, 2001, 37, 1590-1598. (Pubitemid 32778603)
10. Hoffman, H. Polyoxythylenglycerol triricinoleat 35 DAC 1979. Pharm. Ztg, 1984, 129, 1730-1733.
11. Abraxane Healthcare Professional Prescribing Information. http://www.abraxane.com/resources/.pdf. (Accessed September 30, 2010
12. Windebank, A.J.; Blexrud, M.D.; de Groen, P.C. Potential neurotoxicity of the solvent vehicle for cyclosporine. J. Pharmacol. Ex. Ther., 1994, 268, 1051-1056. (Pubitemid 24085913)
13. Irizarry, L.D.; Luu, T.H.; McKoy, J.M.; Samaras, A.T.; Fisher, M.J.; Carias, E.E.; Raisch, D.W.; Calhoun, E.A.; Bennett, C.L. Cremophor EL-containing paclitaxel-induced anaphylaxis: A call to action. Community Oncol., 2009, 6(3), 132-134.
14. Authier, N.; Gillet, J.P.; Fialip, J.; Eschalier, A.; Coudore, F. Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res., 2001, 3, 301-306. (Pubitemid 32962892)
15. Weiss, R.B.; Donehower, R.C.; Wiernik, P.H.; Ohnuma, T.; Gralla, R.J.; Trump, D.L.; Baker, J.R.; Van Echo, D.A.; Von Hoff, D.D.; Leyland-Jones, B. Hypersensitivity reactions from taxol. J. Clin. Oncol., 1990, 8, 1263-1268. (Pubitemid 20195638)
16. Ibrahim, N.K.; Desai, N.; Legha, S.; Soon-Shiong, P.; Theriault, R.L.; Rivera, E.; Esmaeli, B.; Ring, S.E.; Bedikian, A.; Hortobagyi, G.N.; Ellerhorst, J.A. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res., 2002, 8, 1038-1044. (Pubitemid 34517637)
17. Hennenfent, K.L.; Govindan, R. Novel formulations of taxanes: A review. Old wine in a new bottle? Ann. Oncol., 2006, 17, 735-749.
18. Desai, N.P.; Trieu, V.; Hwang, L.Y.; Wu, R.; Soon-Shiong, P.; Gradishar, W.J. Improved effectiveness of nanoparticle albuminbound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs, 2008, 19, 899-909.
19. Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A.; Tao, C.; De, T.; Beals, B.; Dykes, D.; Noker, P.; Yao, R.; Labao, E.; Hawkins, M.; Soon-Shiong, P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res., 2006, 12, 1317-1324. (Pubitemid 43342524)
20. Chin, D.; Boyle, G.M.; Williams, R.M.; Ferguson, K.; Pandeya, N.; Pedley, J.; Campbell, C.M.; Theile, D.R.; Parsons, P.G.; Coman, W.B. Novel markers for poor prognosis in head and neck cancer. Int. J. Cancer, 2005, 113, 789-797. (Pubitemid 40101261)
21. Koukourakis, M.I.; Giatromanolaki, A.; Brekken, R.A.; Sivridis, E.; Gatter, K.C.; Harris, A.L.; Sage, E.H. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res., 2003, 63, 5376-5380. (Pubitemid 37139854)
22. Watkins, G.; Douglas-Jones, A.; Bryce, R.; Mansel, R.E.; Jiang, W.G. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot. Essent. Fatty Acids, 2005, 72, 267-272. (Pubitemid 40342998)
23. Ostacolo, L.; Marra, M.; Ungaro, F.; Zappavigna, S.; Maglio, G.; Quaglia, F.; Abbruzzese, A.; Caraglia, M. In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon- caprolactone) block copolymers: Do nanocarrier properties have a role?. J. Control Release, 2010, Sep 8. [Epub ahead of print].
24. Potmesil, M. Camptothecins: From bench research to hospital wards. Cancer Res., 1994, 54(6), 1431-1439. (Pubitemid 24106402)
25. Ohno, R.; Okada, K.; Masaoka, T.; Kuramoto, A.; Arima, T.; Yoshida, Y.; Ariyoshi, H.; Ichimaru, M.; Sakai, Y.; Oguro, M. An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol., 1990, 8, 1907-1912. (Pubitemid 20382355)
26. Fukuoka, M.; Niitani, H.; Suzuki, A.; Motomiya, M.; Hasegawa, K.; Nishiwaki, Y.; Kuriyama, T.; Ariyoshi, Y.; Negoro, S.; Masuda, N. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 1992, 10, 16-20.
27. Shimada, Y.; Yoshino, M.; Wakui, A.; Nakao, I.; Futatsuki, K.; Sakata, Y.; Kambe, M.; Taguchi, T.; Ogawa, N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol., 1993, 11, 909-913. (Pubitemid 23146086)
28. Redinbo, M.R.; Stewart, L.; Kuhn, P.; Champoux, J.J.; Hol, W.G. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science, 1998, 279, 1504-1513. (Pubitemid 28217069)
29. Stewart, L.; Redinbo, M.R.; Qiu, X.; Hol, W.G.; Champoux, J.J. A model for the mechanism of human topoisomerase I. Science, 1998, 279, 1534-1541. (Pubitemid 28217077)
30. de Jonge, M.J.A.; Sparreboom, A.; Verweij, J. The development of combination therapy involving camptothecins: A review of preclinical and early clinical studies. Cancer Treat. Rev., 1998, 24, 205-220. (Pubitemid 28454215)
31. Iyer, L.; King, C.D.; Whitington, P.F.; Green, M.D.; Tephly, T.R.; Coffman, B.L.; Ratain, M.J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform1A1 in the glucuronidation of its active metabolite (SN-28) in human liver microsomes. J. Clin. Invest., 1998, 101, 847-854. (Pubitemid 28096082)
32. Catimel, G.; Chabot, G.G.; Guastalla, J.P.; Dumortier, A.; Cote, C.; Engel, C.; Gouyette, A.; Mathieu-Boué, A.; Mahjoubi, M.; Clavel, M. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann. Oncol., 1995, 6, 133-140.
33. Gupta, E.; Lestingi, T.M.; Mick, R.; Ramirez, J.; Vokes, E.E.; Ratain, M.J. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res., 1994, 54, 3723-3725. (Pubitemid 24241187)
34. Sugiyama, Y.; Kato, Y.; Chu, X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecifi c organic anion transporter and P-glycoprotein. Cancer Chemother. Pharmacol., 1998, 42(suppl.), S44-49.
35. Rivory, L.P.; Robert, J. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J. Chromatogr. B,Biomed. Appl., 1994, 661, 133-141. (Pubitemid 24341965)
36. Dodds, H.M.; Haaz, M.C.; Riou, J.F.; Robert, J.; Rivory, L.P. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38. J. Pharmacol. Exp. Ther., 1998, 286, 578-583. (Pubitemid 28318036)
37. Haaz, M.C.; Rivory, C.; Riche, C.; Vernillet, L.; Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions. Cancer Res., 1998, 58, 468-472. (Pubitemid 28087408)
38. Lokiec, F.; du Sorbier, B.M.; Sanderink, G.J. Irinotecan (CPT-11) metabolites in human bile and urine. Clin. Cancer Res., 1996, 2, 1943-1949. (Pubitemid 27006626)
39. Santos, A.; Zanetta, S.; Cresteil, T.; Deroussent, A.; Pein, F.; Raymond, E.; Vernillet, L.; Risse, M.L.; Boige, V.; Gouyette, A.; Vassal, G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res., 2000, 6, 2012-2020. (Pubitemid 30305100)
40. Sai, K.; Kaniwa, N.; Ozawa, S.; Sawada, J. A new metabolite of irinotecan whose formation is mediated by human hepatic cytochrome P-450 3A4. Drug Metab. Dispos., 2001, 29, 1505-1513. (Pubitemid 33000700)
41. Fassberg, J.; Stella, V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci., 1992, 81, 676-684. (Pubitemid 23006796)
42. Burke, T.G.; Mi, Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal. Biochem., 1993, 212, 285-287. (Pubitemid 23219487)
43. Burke, T.G.; Munshi, C.B.; Mi, Z.; Jiang, Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J. Pharm. Sci., 1995, 84, 518-519.
44. Sano, K.; Yoshikawa, M.; Hayasaka, S.; Satake, K.; Ikegami, Y.; Yoshida, H.; Ishikawa, T.; Sawada, S.; Tanabe, S. Simple non-ionpaired high-performance liquid chromatographic method for simultaneous quantitation of carboxylate and lactone forms of 14 new camptothecin derivatives. J. Chromatogr. B, Biomed. Appl., 2003, 795, 25-34. (Pubitemid 37289422)
45. Ramesh, M.; Ahlawat, P.; Srinivas, N.R. Irinotecan and its active metabolite, SN-38: Review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed. Chromatogr., 2010, 24(1), 104-23.
46. Wadkins, R.M.; Potter, P.M.; Vladu, B.; Marty, J.; Mangold, G.; Weitman, S.; Manikumar, G.; Wani, M.C.; Wall, M.E; Von Hoff, D.D. Water soluble 20(S)-glycinate ester of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts. Cancer Res., 1999, 59, 3424-3428. (Pubitemid 29334503)
47. Atyabi, F.; Farkhondehfai, A.; Esmaeili, F.; Dinarvand, R. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice. Acta Pharm., 2009, 59(2), 133-144.
48. Chou, T.H.; Chen, S.C.; Chu, I.M. Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method. J. Biosci. Bioeng., 2003, 95, 405-408.
49. Ramsay, E.; Alnajim, J.; Anantha, M.; Taggar, A.; Thomas, A.; Edwards, K.; Karlsson, G.; Webb, M.; Bally, M. Transition metalmediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm. Res., 2006, 23, 2799-2808. (Pubitemid 44885367)
50. Messerer, C.L.; Ramsay, E.C.; Waterhouse, D.; Ng, R.; Simms, E.M.; Harasym, N.; Tardi, P.; Mayer, L.D.; Bally, M.B. Liposomal irinotecan: Formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin. Cancer Res., 2004, 10, 6638-6649. (Pubitemid 39346561)
51. Ramsay, E.; Alnajim, J.; Anantha, M.; Zastre, J.; Yan, H.; Webb, M.; Waterhouse, D.; Bally, M. A novel liposomal irinotecan formulation with significant anti-tumour activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. Eur. J. Pharm. Biopharm., 2008, 68(3), 607-617. (Pubitemid 351318211)
52. Drummond, D.C.; Noble, C.O.; Guo, Z.; Hong, K.; Park, J.W.; Kirpotin, D.B. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy, Cancer Res., 2006, 66, 3271-3277.
53. Diallo, J.S.; Peant, B.; Lessard, L.; Delvoye, N.; Le, P.C.; Mes-Masson, A.M.; Saad, F. An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines. Prostate, 2006, 66, 1245-1256. (Pubitemid 44384300)
54. Weglarz, L.; Molin, I.; Orchel, A.; Parfiniewicz, B.; Dzierzewicz, Z. Quantitative analysis of the level of p53 and p21(WAF1) mRNA in human colon cancer HT-29 cells treated with inositol hexaphosphate. Acta Biochim. Pol., 2006, 53, 349-356. (Pubitemid 44033933)
55. Saied, I.T.; Shamsuddin, A.M. Up-regulation of the tumor suppressor gene p53 and WAF1 gene expression by IP6 in HT-29 human colon carcinoma cell line. Anticancer Res., 1998, 18, 1479-1484. (Pubitemid 28342549)
56. Hattori, Y.; Shi, L.; Ding, W.; Koga, K.; Kawano, K.; Hakoshima, M.; Maitani, Y. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J. Control Release, 2009, 136(1), 30-37.
57. Riedl, S.J.; Salvesen G.S. The apoptosome: Signalling platform of cell death. Nature Reviews Molecular Cell, 2007, 8, 405-413. (Pubitemid 46643237)
58. Kuang, A.A.; Diehl, G.; Zhang, J.; Winoto. A. FADD is required for DR4-and DR5-mediated apoptosis: Lack of TRAILinduced apoptosis in FADD-deficient mouse embryonic fibroblasts. J. Biol. Chem., 2000, 275:25065-8.
59. Nagata. Fas-mediated apoptosis. Adv.Exp. Med. Biol. 1996, 406:119-24.
60. Kischkel, F.C.; Hellbardt, S.; Behrmann, I.; Germer, M.; Pawlita, M.; Krammer, P.H.; Peter, M.E. Cytotoxicity-dependent APO-1 (Fas/CD95)- associatedproteins from a death-inducing signaling complex (DISC) with the receptor. EMBO J., 1995, 14, 5579-88.
61. Denault and Salvesen. Caspase: Keys in the ignition of cell death. Chem. Rev., 2002, 102 (12): 4489-500.
62. Zhang, W.; Elimban, V.; Nijjar, M.S.; Gupta, S.K.; Dhalla, N.S. Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure. Exp. Clin. Cardiol., 2003, 8, 173-183. (Pubitemid 38923454)
63. Lorenz, K.; Schmitt, J.P.; Vidal, M.; Lohse, M.J. Cardiac hypertrophy: Targeting Raf/MEK/ERK1/2-signaling. Int. J. Biochem. Cell Biol., 2009, 41, 2351-2355.
64. Petrich, B.G.; Wang, Y.; Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc. Med., 2004, 14, 50-55. (Pubitemid 38340846)
65. Laderoute, K.R.; Webster, K.A. Hypoxia/reoxygenation stimulates Jun kinase activity through redox signaling in cardiac myocytes. Circ. Res., 1997, 80, 336-344. (Pubitemid 27093347)
66. Xia, Z.; Dickens, M.; Raingeaud, J.; Davis, R.J.; Greenberg, M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 1995, 270, 1326-1331.
67. Matsui, T.; Tao, J.; del Monte, F.; Lee, K.H.; Li, L.; Picard, M.; Force, T.L.; Franke, T.F.; Hajjar, R.J.; Rosenzweig, A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation, 2001, 104, 330-335. (Pubitemid 32666956)
68. Matsui, T.; Davidoff, A.J. Assessment of PI-3 kinase and Akt in ischemic heart diseases in diabetes. Methods Mol. Med., 2007, 139, 329-338.
69. Chao, W.; Matsui, T.; Novikov, M.S.; Tao, J.; Li, L.; Liu, H.; Ahn, Y.; Rosenzweig, A. Strategic advantages of insulin-like growth factor-I expression for cardioprotection. J. Gene Med., 2003, 5, 277-286. (Pubitemid 40310380)
70. Hong, F.; Kwon, S.J.; Jhun, B.S.; Kim, S.S.; Ha, J.; Kim, S.J.; Sohn, N.W.; Kang, C.; Kang, I. Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signalregulated kinase pathways. Life Sci., 2001, 68, 1095-1105. (Pubitemid 32168036)
71. Lai, H.C.; Liu, T.J.; Ting, C.T.; Sharma, P.M.; Wang, P.H. Insulinlike growth factor-1 prevents loss of electrochemical gradient in cardiac muscle mitochondria via activation of PI 3 kinase/Akt pathway. Mol. Cell. Endocrinol., 2003, 205, 99-106. (Pubitemid 37297355)
72. Fukazawa, R.; Miller, T.A.; Kuramochi, Y.; Frantz, S.; Kim, Y.D.; Marchionni, M.A.; Kelly, R.A.; Sawyer, D.B. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J. Mol. Cell. Cardiol., 2003, 35, 1473-1479. (Pubitemid 37491190)
73. Childs, A.C.; Phaneuf, S.L.; Dirks, A.J.; Phillips, T.; Leeuwenburgh, C. Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res., 2002, 62, 4592-4598.
74. An, J.; Li, P.; Li, J.; Dietz, R.; Donath, S. ARC is a critical cardiomyocyte survival switch in doxorubicin cardiotoxicity. J. Mol. Med., 2009, 87, 401-410.
75. Sorensen, B.S.; Sinding, J.; Andersen, A.H.; Alsner, J.; Jensen, P.B.; Westergaard, O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. J. Mol. Biol., 1992, 228, 778-786. (Pubitemid 23017269)
76. Cheng, H.; Force, T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog. Cardiovasc. Dis., 2010, 53(2), 114-120.
77. Sawyer, D.B.; Peng, X.; Chen, B.; Pentassuglia, L.; Lim, C.C. Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection? Prog. Cardiovasc. Dis., 2010, 53(2), 105-113.
78. O'Brien, M.E.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D.G.; Tomczak, P.; Ackland, S.P.; Orlandi, F.; Mellars, L.; Alland, L.; Tendler, C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol., 2004, 15(3), 440-449. (Pubitemid 38444547)
79. Gabizon, A.A. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest., 2001, 19(4), 424-436. (Pubitemid 32525189)
80. Ranson, M.R.; Carmichael, J.; O'Byrne, K.; Stewart, S.; Smith, D.; Howell, A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J. Clin. Oncol., 1997, 15(10), 3185-3191. (Pubitemid 27419330)
81. Hamilton, A.; Biganzoli, L.; Coleman, R.; Mauriac, L.; Hennebert, P.; Awada, A.; Nooij, M.; Beex, L.; Piccart, M.; Van Hoorebeeck, I.; Bruning, P.; de Valeriola, D. EORTC 10968: A phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. Ann. Oncol., 2002, 13(6), 910-918. (Pubitemid 34752687)
82. Smith, D.H.; Adams, J.R.; Johnston, S.R.; Gordon, A.; Drummond, M.F.; Bennett, C.L. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann. Oncol., 2002, 13(10), 1590-1597. (Pubitemid 35331456)
83. Bennett, C.L.; Calhoun, E.A. Pharmacoeconomics of liposomal anthracycline therapy. Semin. Oncol., 2004, 31(6 Suppl. 13), 191-195. (Pubitemid 40023248)
84. Bates, M.; Lieu, D.; Zagari, M.; Spiers, A.; Williamson, T. A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. Clin. Ther., 1997, 19(1), 167-184. (Pubitemid 27186448)
85. Allen, T.M.; Cullis, P.R. Drug Delivery Systems: Entering the Mainstream. Science, 2004, 303, 1818-1822. (Pubitemid 38374867)
86. Fleisch, H. Development of bisphosphonates. Breast Cancer Res., 2002, 4, 30-34. (Pubitemid 34097554)
87. Green, J.R. Antitumor effects of bisphosphonates. Cancer, 2003, 97, 840-847. (Pubitemid 36125821)
88. Soma, M.R.; Corsini, A.; Paoletti, R. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol. Lett., 1992, 64-65.
89. Rogers, M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des., 2003, 9, 2643-2658. (Pubitemid 37456015)
90. Rogers, M.J. From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif. Tissue Int., 2004, 75, 451-461. (Pubitemid 40174502)
91. Reid, T.S.; Terry, K.L.; Casey, P.J.; Beese, L.S. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J. Mol. Biol., 2004, 343, 417-433. (Pubitemid 39296875)
92. Santini, D.; Caraglia, M.; Vincenzi, B.; Holen, I.; Scarpa, S.; Budillon, A.; Tonini, G. Mechanisms of Disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat. Clin. Pract. Oncol., 2006, 3(6), 325-338. (Pubitemid 43871543)
93. Green, J.R. Bisphosphonates: Preclinical review. Oncologist, 2004, 9(Suppl 4):S3-S13.
94. Saad, F.; Gleason, D.M.; Murray, R.; Tchekmedyian, S.; Venner, P.; Lacombe, L.; Chin, J.L.; Vinholes, J.J.; Goas, J.A.; Zheng, M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst., 2004, 96, 879-882. (Pubitemid 38807610)
95. Lipton, A.; Seaman, J.; Zheng, M. Long-term efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. In: What is new in bisphosphonates? Seventh workshop on bisphosphonates-from the laboratory to the patient. Davos, Switzerland, March 24-26, 2004.
96. Caraglia, M.; D'Alessandro, A.M.; Marra, M.; Giuberti, G.; Vitale, G.; Viscomi, C.; Colao, A.; Prete, S.D.; Tagliaferri, P.; Tassone, P.; Budillon, A.; Venuta, S.; Abbruzzese, A. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene, 2004, 23, 6900-6913. (Pubitemid 39279991)
97. Caraglia, M.; Marra, M.; Leonetti, C.; Meo, G.; D'Alessandro, A.M.; Baldi, A.; Santini, D.; Tonini, G.; Bertieri, R.; Zupi, G.; Budillon, A.; Abbruzzese, A. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J. Cell. Physiol., 2007, 211(2), 533-543. (Pubitemid 46580107)
98. Santini, D.; Caraglia, M.; Vincenzi, B.; Holen, I.; Scarpa, S.; Budillon, A.; Tonini, G. Mechanisms of Disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat. Clin. Pract. Oncol., 2006, 3(6), 325-338. (Pubitemid 43871543)
99. Marra, M., Salzano, G., Legnetti, C., Tassone, P., Scarsella, M., Zappavigna, S., Calmieri, T., Franco, R., Liguori, G., Cigliana, G., Ascani, R., La Rotonda, M.I., Abruzzese, A., Tagliaferro, P., Caraglia, M., De Rosa, G. anotechnologies to use bisphosphonates as potent anticancer agents: The effects of zoledronic acid encapsulated into liposomes. Nanomedicine., 2011 Mar 29.
100. Salzano, G., Marra, M., Porru, M., Zappavigna, S., Abbruzzese, A., La Rotonda, M.I., Legnetti, C., Caraglia, M., De Rosa, G. Selfassembly nanoparticles for the delivery of bisphosphonates into tumors. Int. J. Pharm., 2011, 17, 292-7.
101. Caraglia, M.; Santini, D.; Marra, M.; Vincenzi, B.; Tonini, G.; Budillon, A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr. Relat. Cancer, 2006, 13, 7-26.
102. Caraglia, M.; Marra, M.; Naviglio, S.; Botti G.; Addeo, R.; Abbruzzese, A. Zoledronic acid: An unending tale for an antiresorptive agent. Expert Opin. Pharmacother., 2010, 11(1), 141-154.
103. Chen, T. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol., 2002, 42, 1228-1236. (Pubitemid 35205058)
104. Skerjanec, A.; Berenson, J.; Hsu, C.; Major, P.; Miller, W.H.Jr; Ravera, C.; Schran, H.; Seaman, J.; Waldmeier, F. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J. Clin. Pharmacol., 2003, 43, 154-162. (Pubitemid 36125942)
105. Weiss, H.M.; Pfaar, U.; Schweitzer, A.; Wiegand, H.; Skerjanec, A.; Schran, H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab. Dispos., 2008, 36(10), 2043-2049.
106. Shmeeda, H.; Amitay, Y.; Gorin, J.; Tzemach, D.; Mak, L.; Ogorka, J.; Kumar, S.; Zhang, J.A.; Gabizon, A. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J. Control Release, 2010, 146(1), 76-83.
107. Allen, T.M. Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Cancer, 2002, 2(10), 750-763. (Pubitemid 37328910)
108. Huwyler, J.; Wu, D.; Pardridge, W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(24), 14164-14169. (Pubitemid 26424263)
109. Chowdhary, R.K.; Sharif, I.; Chansarkar, N.; Dolphin, D.; Ratkay, L.; Delaney, S.; Meadows, H. Correlation of photosensitizer delivery to lipoproteins and efficacy in tumor and arthritis mouse models; comparison of lipid-based and Pluronic P123 formulations. J. Pharm. Pharm. Sci., 2003, 6(2), 198-204. (Pubitemid 37207224)
110. Bolotin, E.M.; Cohen, R.; Bar. L.K.; Emmanuel, N.; Ninio, S.; Lasic, D.D.; Barenholz, Y. Ammonium sulfate gradients for efficient and stable remote loading of amphipatic weak bases into liposomes and ligando liposomes. J. Liposome Res., 1994, 4, 455-479. (Pubitemid 24130556)
111. Cullis, P.R.; Hope, M.J.; Bally, M.B.; Madden, T.D.; Mayer, L.D. Fenske DB.Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta, 1997, 1331(2), 187-211. (Pubitemid 27387443)
112. Northfelt, D.W.; Martin, F.J.; Working, P.; Volberding, P.A.; Russell, J.; Newman, M.; Amantea, M.A.; Kaplan, L.D. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol., 1996, 36(1), 55-63. (Pubitemid 26058811)
113. Vasey, P.A.; Kaye, S.B.; Morrison, R.; Twelves, C.; Wilson, P.; Duncan, R.; Thomson, A.H.; Murray, L.S.; Hilditch, T.E.; Murray, T.; Burtles, S.; Fraier, D.; Frigerio, E.; Cassidy, J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res., 1999, 5(1), 83-94. (Pubitemid 29045181)
114. Harris, J.M.; Chess, R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov., 2003, 2(3), 214-221. (Pubitemid 37361666)
115. Gabizon, A.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin. Pharmacokinet., 2003, 42(5), 419-436. (Pubitemid 36649037)
116. Cabanes, A.; Briggs, K.E.; Gokhale, P.C.; Treat, J.A.; Rahman, A. Comparative in vivo studies with paclitaxel and liposomeencapsulated paclitaxel. Int. J. Oncol., 1998, 12(5), 1035-1040. (Pubitemid 28186763)
117. Meerum Terwogt, J.M.; Groenewegen, G.; Pluim, D.; Maliepaard, M.; Tibben, M.M.; Huisman, A.; ten Bokkel Huinink, W.W.; Schot, M., Welbank, H.; Voest, E.E.; Beijnen, J.H.; Schellens, J.M. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother. Pharmacol., 2002, 49, 201-210. (Pubitemid 34185593)
118. Gelmon, K.A.; Tolcher, A.; Diab, A.R.; Bally, M.B.; Embree, L.; Hudon, N.; Dedhar, C.; Ayers, D.; Eisen, A.; Melosky, B.; Burge, C.; Logan, P.; Mayer. L.D. Phase I study of liposomal vincristine. J. Clin. Oncol., 1999, 17(2), 697-705. (Pubitemid 29075259)
119. Tardi, P.; Choice, E.; Masin, D.; Redelmeier, T.; Bally, M.; Madden, T.D. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res., 2000, 60(13), 3389-3393. (Pubitemid 30482152)
120. Papahadjopoulos, D.; Allen, T.M.; Gabizon, A.;, Mayhew, E.; Matthay, K.; Huang, S.K.; Lee, K.D.; Woodle, M.C.; Lasic, D.D.; Redemann, C.; Martin F.J. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A., 1991, 88(24), 11460-11464. (Pubitemid 21916061)
121. Allen, T.M.; Cleland, L.G. Serum-induced leakage of liposome contents. Biochim. Biophys. Acta, 1980, 597(2), 418-426. (Pubitemid 10066496)
122. Horowitz, A.T.; Barenholz, Y.; Gabizon, A.A. In vitro cytotoxicity of liposome-encapsulated doxorubicin: Dependence on liposome composition and drug release. Biochim. Biophys. Acta, 1992, 1109(2), 203-209.
123. Yuan, F.; Leunig, M.; Huang, S.K.; Berk, D.A.; Papahadjopoulos, D.; Jain, R.K. Microvascular permeability and interstitial penetra tion of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res., 1994, 54(13), 3352-3356. (Pubitemid 24225946)
124. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control Release, 2000, 65(1-2), 271-284. (Pubitemid 30122932)
125. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J.W.; Thurston, G.; Roberge, S.; Jain, R.K.; McDonald, D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 2000, 156(4), 1363-1380. (Pubitemid 30660013)
126. Simionescu, M.;, Simionescu, N.; Palade, G.E. Morphometric data on the endothelium of lood capillaries. J. Cell. Biol., 1974, 60, 128-152.
127. Simionescu, M.;, Simionescu, N.; Palade, G.E. Structural basis of permeability in sequential segments of the microvasculature. I. Bipolar microvascular fields in the diaphragm. Microvasc. Res., 1978, 15, 1-16. (Pubitemid 8303526)
128. Simionescu, M.; Simionescu, N.; Palade, G.E. Differentiated microdomains on the luminal surface of the capillary endothelium. I. Partial characterization of their anionic sites. J. Cell. Biol., 1981, 90, 614-621. (Pubitemid 12254917)
129. Movat, H.Z. The role of histamine and other mediators in microvascular changes in acute inflammation. Can. J. Physiol. Pharmacol., 1987, 65, 451-457. (Pubitemid 17068325)
130. Mylecharane, E.J. Mechanisms involved in serotonin-induced vasodilation. Blood Vessels, 1990, 27, 116-126.
131. Vercellotti, G.M.; Tolins, J.P. Endothelial activation and the kidney: Vasomediator modulation and antioxidant strategies. Am. J. Kidney Dis., 1993, 21, 331-343. (Pubitemid 23100351)
132. van Hinsbergh, V.W. The endothelium: Vascular control of haemostasis. Atherosclerosis, 2001, 95, 198-201. (Pubitemid 32297718)
133. Hobbs, S.K.; Monsky, W.L.; Yuan, F.; Roberts, G.; Griffith, L.; Torchilin, V.P.; Jain, R.K. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 4607-4612. (Pubitemid 28207960)
134. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D.A.; Torchilin, V.P.; Jain, R.K. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res., 1995, 55, 3752-3756.
135. Jain, R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev., 1990, 9, 253-266. (Pubitemid 20380382)
136. Jain, R.K.; Carmeliet, P.F. Vessels of death or life. Sci. Am., 2001, 285, 38-45.
137. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev., 1987, 6(4), 559-593.
138. Netti, P.A.; Roberge, S.; Boucher, Y.; Baxter, L.T.; Jain, R.K. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: A proposed mechanism for tumor blood flow heterogeneity. Microvasc. Res., 1996, 52(1), 27-46. (Pubitemid 26245691)
139. Schiffelers, R.M. , Storm, G.; Bakker-Woudenberg, I.A. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm. Res., 2001, 18(6), 780-787. (Pubitemid 32783513)
140. Edens, H.A.; Levi, B.P.; Jaye, D.L.; Walsh, S.; Reaves, T.A.; Turner, J.R.; Nusrat, A.; Parkos, C.A. Neutrophil transepithelial migration: Evidence for sequential, contact-dependent signaling events and enhanced paracellular permeability independent of transjunctional migration. J. Immunol., 2002, 169(1), 476-486. (Pubitemid 34686170)
141. Glantz, M.J.; Jaeckle, K.A.; Chamberlain, M.C.; Phuphanich, S.; Recht, L.; Swinnen, L.J.; Maria, B.; LaFollette, S.; Schumann, G.B.; Cole, B.F.; Howell, S.B. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res., 1999, 5(11), 3394-3402.
142. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47(1), 65-81. (Pubitemid 32209233)
143. Mehvar, R. Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: Pharmacokinetic and pharmacodynamic perspectives. Curr. Pharm. Biotechnol., 2003, 4(5), 283-302. (Pubitemid 37220861)
144. LaVan, D.A.; McGuire, T.; Langer, R. Small-scale systems for in vivo drug delivery. Nat. Biotechnol., 2003, 21(10), 1184-1191. (Pubitemid 37186175)
145. Guo, X.; Szoka, F.C.Jr. Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc. Chem. Res., 2003, 36(5), 335-341.
146. Alberts, D.S.; Garcia, D.J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs, 1997, 54 Suppl 4, 30-35. (Pubitemid 27487793)
147. Szebeni, J.; Baranyi, L.; Savay, S.; Milosevits, J.; Bunger, R.; Laverman, P.; Metselaar, J.M.; Storm, G.; Chanan-Khan, A.; Liebes, L.; Muggia, F.M.; Cohen, R.; Barenholz, Y.; Alving, C.R. Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: Experimental and clinical studies. J. Liposome Res., 2002, 12(1-2), 165-172. (Pubitemid 34846969)
148. Senter, P.D.; Springer, C.J. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Deliv. Rev., 2001, 53(3), 247-264. (Pubitemid 34024909)
149. Uziely, B.; Jeffers, S.; Isacson, R.; Kutsch, K.; Wei-Tsao, D.; Yehoshua, Z.; Libson, E.; Muggia, F.M.; Gabizon, A. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol., 1995, 13(7), 1777-1785.
150. Samuels, B.L.; Vogelzang, N.J.; Ruane, M.; Simon, M.A. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat. Rep., 1987, 71(10), 971-972. (Pubitemid 17151377)
151. Lotem, M.; Hubert, A.; Lyass, O.; Goldenhersh, M.A.; Ingber, A.; Peretz, T.; Gabizon, A. Skin toxic effects of polyethylene glycolcoated liposomal doxorubicin. Arch. Dermatol., 2000, 136(12), 1475-1480. (Pubitemid 32009267)
152. Wang, A.Z.; Gu, F.; Zhang, L.; Chan, J.M.; Radovic-Moreno, A.; Shaikh, M.R.; Farokhzad, O.C. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin. Biol. Ther., 2008, 8, 1063-1070.
153. Wagner, E.; Curiel, D.; Cotten, M. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv. Drug Deliv. Rev., 1994, 14, 113-135. (Pubitemid 24131676)
154. Garg, A.; Tisdale, A.W.; Haidari, E.; Kokkoli, E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm., 2009, 366, 201-210.
155. Ishida, O.; Maruyama, K.; Tanahashi, H.; Iwatsuru, M.; Sasaki, K.; Eriguchi, M.; Yanagie, H. Liposomes bearing polyethyleneglycolcoupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res., 2001, 18, 1042-1048. (Pubitemid 32799953)
156. Zhang, Y.; Zhang, Y.F.; Bryant, J.; Charles, A.; Boado, R.J.; Pardridge, W.M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res., 2004, 10, 3667-3677. (Pubitemid 38697600)
157. Tang, Y.; Scollard, D.; Chen, P.; Wang, J.; Holloway, C.; Reilly, R.M. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNICtrastuzumab (Herceptin) Fab fragments. Nucl. Med. Commun., 2005, 26, 427-432. (Pubitemid 40617731)
158. Laginha, K.M.; Moase, E.H.; Yu, N.; Huang, A.; Allen, T.M. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. J. Drug Target, 2008, 16, 605-610.
159. Maruyama, K.; Takahashi, N.; Tagawa, T.; Nagaike, K.; Iwatsuru, M. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett., 1997, 413, 177-180. (Pubitemid 27348659)
160. Kirpotin, D.; Park, J.W.; Hong, K.; Zalipsky, S.; Li, W.L.; Carter, P.; Benz, C.C. Papahadjopoulos D.Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro. Biochemistry, 1997, 36, 66-75. (Pubitemid 27024679)
161. Yang, L.; Mao, H.; Wang, Y.A.; Cao, Z.; Peng, X.; Wang, X.; Duan, H.; Ni, C.; Yuan, Q.; Adams, G.; Smith, M.Q.; Wood, W.C.; Gao, X.; Nie, S. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small, 2009, 5, 235-243.
162. Yang, L.; Peng. X.H.; Wang, Y.A.; Wang, X.; Cao, Z.; Ni, C.; Karna, P.; Zhang, X.; Wood W.C.; Gao, X.; Nie, S.; Mao, H. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer Res., 2009, 15, 4722-4732.
163. Stoppelli, M.P.; Corti, A.; Soffientini, A.; Cassani, G.; Blasi, F.; Assoia, R.K. Differentiation-enhanced binding of the aminoterminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. U.S.A., 1985, 82, 4939-4943. (Pubitemid 15249921)
164. Huai, Q.; Mazar, A.P.; Kuo, A.; Parry, G.C.; Shaw, D.E.; Callahan, J.; Li, Y.; Yuan, C.; Bian, C.; Chen, L.; Furie, B.; Furie, B.C.; Cines, D.B.; Huang, M. Structure of human urokinase plasminogen activator in complex with its receptor. Science, 2006, 311, 656-659. (Pubitemid 43191309)
165. Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol., 1996, 12, 697-715. (Pubitemid 26422728)
166. Pasqualini, R.; Koivunen, E.; Ruoslahti, E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol., 1997, 15, 542-546. (Pubitemid 27251571)
167. Schiffelers, R.M.; Koning, G.A.; ten Hagen, T.L.; Fens, M.H.; Schraa, A.J.; Janssen, A.P.; Kok, R.J.; Molema, G.; Storm, G. Antitumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control Release, 2003, 91, 115-122. (Pubitemid 37288882)
168. Banerjee, R.; Tyagi, P.; Li, S.; Huang, L. Anisamide-targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer, 2004, 112, 693-700. (Pubitemid 39425952)
169. Li, S.D.; Chono, S.; Huang, L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther., 2008, 16, 942-946. (Pubitemid 351587105)
170. Weitman, S.D.; Lark, R.H.; Coney, L.R.; Fort, D.W.; Frasca, V.; Zurawski, V.R.Jr.; Kamen, B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res., 1992, 52, 3396-3401.
171. Goren, D.; Horowitz, A.T.; Tzemach, D.; Tarshish, M.; Zalipsky, S.; Gabizon, A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res., 2000, 6, 1949-1957. (Pubitemid 30305094)
172. Pan, X,: Lee, R.J. Tumour-selective drug delivery via folate receptor-targeted liposomes. Expert Opin. Drug Deliv., 2004, 1, 7-17. (Pubitemid 40297953)
173. Paulos, C.M.; Reddy, J.A.; Leamon, C.P.; Turk, M.J.; Low, P.S. Ligand binding and kinetics of folate receptor recycling in vivo: Impact on receptor-mediated drug delivery. Mol. Pharmacol., 2004, 66, 1406-1414. (Pubitemid 39564767)
174. Mendelsohn, J.; Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene, 2000, 19, 6550-6565. (Pubitemid 32197693)
175. Holmes, W.E.; Sliwkowski, M.X.; Akita, R.W.; Henzel, W.J.; Lee, J.; Park, J.W.; Yansura, D.; Abadi, N.; Raab, H.; Lewis, G.D.; Shepard, H.M.; Kuang, W.J.; Wood, W.; Goeddel, D.V.; Vandlen, R.L. Identification of heregulin. A specific activator of P185ERBB2. Science, 1992, 256, 1205-1210.
176. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses ER2. New Engl. J. Med., 2001, 344, 783-792. (Pubitemid 32222155)
177. Park, J.W.; Hong, K.;, Kirpotin, D.B.; Colbern, G.; Shalaby, R.; Baselga, J.; Shao, Y.; Nielsen, U.B.; Marks, J.D.; Moore, D.; Papahadjopoulos, D.; Benz, C.C. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin. Cancer Res., 2002, 8, 1172-1181. (Pubitemid 35177372)
178. Xiong, X.B.; Huang, Y.; Lu, W.L.; Zhang, X.; Zhang, H.; Nagai, T.; Zhang, Q. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J. Control Release, 2005, 107, 262-275. (Pubitemid 41316289)
179. Elbayoumi, T.A.; Torchilin, V.P. Enhanced accumulation of longcirculating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: Gammaimaging studies. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, 1196-1205. (Pubitemid 44484476)
180. Gabizon, A.; Horowitz, AT.; Goren, D.; Tzemach, D.; Shmeeda, H.; Zalipsky, S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res., 2003, 9, 6551-5559.
181. Zalipsky, S.; Puntambekar, B.; Boulikas, P.; Engbers, C.M.; Woodle, M.C. Peptide attachment to extremities of liposomal surface grafted PEG chains: Preparation of the long-circulating form of laminin pentapeptide, YIGSR. Bioconjug. Chem., 1995, 6, 705-708.
182. Fens, M.H.; Hill, K.J.; Issa, J.; Ashton, S.E.; Westwood, F.R.; Blakey, D.C.; Storm, G.; Ryan, A.J.; Schiffelers, R.M. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. Br. J. Cancer, 2008, 99, 1256-1264.
183. Allen, T.M.; Hansen, C.; Martin, F.; Redemann, C.; Yauyoung, A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta, 1991, 1066, 29-36.
184. Wang, M.; Lowik, D.W.; Miller, A.D.; Thanou, M. Targeting the urokinase plasminogen activator receptor with synthetic selfassembly nanoparticles. Bioconjug. Chem., 2009, 20, 32-40.
185. Demirgoz, D.; Garg, A.; Kokkoli, E. PR b-targeted PEGylated liposomes for prostate cancer therapy. Langmuir, 2008, 24, 13518-13524.
186. Sawant, R.R.; Sawant, R.M.; Kale, A.A.; Torchilin, V.P. The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells. J. Drug Target, 2008, 16, 596-600.
187. Gantert, M.; Lewrick, F.; Adrian, J.E.; Rössler, J.; Steenpass, T.; Schubert, R.; Peschka-Süss, R. Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors. Pharm. Res., 2009, 26, 529-538.
188. Gu, F., Zhang, L.; Teply, B.A.; Mann, N.; Wang, A.; Radovic-Moreno, A.F.; Langer, R.; Farokhzad, O.C. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 2586-2591. (Pubitemid 351520557)
189. Shmeeda, H.; Tzemach, D.; Mak, L.; Gabizon, A. Her2-targeted pegylated liposomal doxorubicin: Retention of target-specific binding and cytotoxicity after in vivo passage. J. Control Release, 2009, 136, 155-160.
190. Kirpotin, D.B.; Drummond, D.C.; Shao, Y.; Shalaby, M.R.; Hong, K.; Nielsen, U.B.; Marks, J.D.; Benz, C.C.; Park, J.W. Antibody targeting of longcirculating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res., 2006, 66, 6732-6740. (Pubitemid 44085631)
191. Kamaly, N.; Kalber, T.; Thanou, M.; Bell, J.D.; Miller, A.D. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconjug.Chem., 2009, 20, 648-655.
192. Elbayoumi, T.A.; Pabba, S.; Roby, A.; Torchilin, V.P. Antinucleosome antibodymodified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J. Liposome Res., 2007, 17, 1-14. (Pubitemid 46631140)
193. Song, S.; Liu, D.; Peng, J.; Deng, H.; Guo, Y.; Xu, L.X.; Miller, A.D.; Xu, Y. Novel peptide ligand directs liposomes toward EGFR high-expressing cancer cells in vitro and in vivo. FASEB J., 2009, 23, 1396-1404.
194. Turk, M.J.; Waters, D.J.; Low, P.S. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett., 2004, 213, 165-172. (Pubitemid 39140974)
195. Alizadeh, D.; Zhang, L.; Hwang, J.; Schluep, T.; Badie, B. Tumorassociated macrophages are predominant carriers of cyclodextrinbased nanoparticles into gliomas. Nanomedicine, 2009, 6, 82-90.
196. Stevens, P.J.; Sekido,M.; Lee, R.J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm. Res., 2004, 21, 2153-2157. (Pubitemid 40568428)
197. Leimgruber, A.; Berger, C.; Cortez-Retamozo, V.; Etzrodt, M.; Newton, A.P.; Waterman, P.; Figueiredo, J.L.; Kohler, R.H.; Elpek, N.; Mempel, T.R.; Swirski, F.K.; Nahrendorf, M.; Weissleder, R.; Pittet, M.J. Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasia, 2009, 11, 459-468.